SCHEMBL17828189

SCHEMBL17828189

COC(=O)CCCCN1CCC(C)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.54
POLB P06746 1/20 0.53
HTT P42858 1/20 0.53
HTR7 P34969 3/20 0.50
KMT2A Q03164 3/20 0.50
HRH3 Q9Y5N1 6/20 0.47
MEN1 O00255 1/20 0.47
CHRM2 P08172 1/20 0.47
HTR1A P08908 1/20 0.47
ADRA2A P08913 1/20 0.47
DRD1 P21728 1/20 0.47
ADRA1A P35348 1/20 0.47
OPRM1 P35372 1/20 0.47
DRD3 P35462 1/20 0.47
KCNH2 Q12809 1/20 0.47
TSHR P16473 1/20 0.45
PAOX Q6QHF9 1/20 0.45
CARM1 Q86X55 1/20 0.44
PRMT6 Q96LA8 1/20 0.44
PRMT1 Q99873 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14375246 0.98 SMN1; SMN2 (0.53) SMN1; SMN2POLBHTTHTR7KMT2A
SCHEMBL5231802 0.88 SMN1; SMN2 (0.68) SMN1; SMN2POLBHTTKMT2AHRH3
SCHEMBL24001294 0.84 SMN1; SMN2 (0.55) SMN1; SMN2POLBHTTHTR7CHRM2
Hydrochloric Acid SCHEMBL28920811 0.83 GNAI3 (0.57) SMN1; SMN2POLBHTTHTR7CHRM2
SCHEMBL25751543 0.82 TSHR (0.52) SMN1; SMN2KMT2AHRH3HTR1AADRA2A
SCHEMBL30258617 0.81 SMN1; SMN2 (0.52) SMN1; SMN2POLBHTTHTR7KMT2A
SCHEMBL2847771 0.81 HTR7 (0.54) SMN1; SMN2POLBHTTHTR7KMT2A
SCHEMBL9856869 0.81 SMN1; SMN2 (0.53) SMN1; SMN2POLBHTR7KMT2AHRH3
SCHEMBL28390299 0.81 PAOX (0.53) SMN1; SMN2HTR7KMT2AHRH3HTR1A
SCHEMBL25287464 0.80 SMN1; SMN2 (0.51) SMN1; SMN2HTR7KMT2ACHRM2OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9586951-B2 Morpholine derivative or salt thereof FUJIFILM CORPORATION (JP) 2017-03-07 US disclosed
US-9586951-B2 Morpholine derivative or salt thereof FUJIFILM CORPORATION (JP) 2017-03-07 US disclosed
EP-3042900-A1 NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF Fujifilm Corporation (JP) 2016-07-13 EP disclosed
US-20160168139-A1 NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2016-06-16 US disclosed
US-20160168139-A1 NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2016-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160168139-A1 NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF PRMT7, RBBP7, RER1 SMN1; SMN2 1734/4885POLB 4001/4885HTT 3547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.